Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease.

This Phase 3 clinical trial tested a methylene blue derivative called HMTM in patients with mild cognitive impairment and early Alzheimer’s disease. The compound works by targeting tau protein tangles in the brain, which are a hallmark of Alzheimer’s. The study measured clinical outcomes, brain imaging changes, and blood markers to assess whether the treatment could slow cognitive decline or improve symptoms.

For your business

Methylene blue derivatives have shown promise in Phase 3 trials for protecting against cognitive decline by targeting the toxic protein tangles that damage brain cells in Alzheimer’s disease.